ClinTec International, a global CRO with a presence in over 40 countries worldwide, recently announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec's global team with access to a new patient population, but will also further consolidate the British CRO's presence in the Middle East and North Africa (MENA) region. The office adds to the company's current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.

Speaking at the an nouncement of ClinTec's new office, the company's founder and CEO, Dr. Rabinder Buttar commented, "The launch of this new office in Turkey confirms ClinTec International's reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey and the wider MENA region to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole."

The announcement ClinTec's new Turkey office coincides with the company sponsoring the partnerships in Clinical Trials Russia-CIS & MENA-Turkey conference held in Istanbul on 22-23rd May 2013. The conference aims to explore the challenges and opportunities facing companies when conducting clinical trials in the MENA region and looks for the leading CROs within the region to provide solutions and advice on this complex market. As such, ClinTec's executive vice-president-Global Clinical Development, Bindhya Cariappa, will be delivering a speech on Rare Disease Trials in the MENA region.

ClinTec is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company's President and CEO. ClinTec has a presence in over 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.